Harnessing AI for Healthcare: A New Dawn for South Africa

By Sumona Bose

February 7, 2024

The Need for AI-Driven Healthcare Policy in South Africa

South Africa’s healthcare sector is on the brink of a transformative era, with artificial intelligence (AI) at its helm. However, the current policy frameworks are ill-equipped to foster innovation in this burgeoning field. Five key issues demand immediate attention: outdated legislation, data and algorithmic bias, workforce impact, liability dilemmas, and a dearth of AI system innovation. The establishment of a comprehensive national policy framework addressing these concerns is crucial for the safe, responsible, and regulated adoption of AI in healthcare.

The Innovation Gap: AI Patenting in South Africa

A closer look at the patenting activity within AI in South Africa reveals a stark reality. Despite the country being listed in over 9,000 AI patent applications between 2012 and 2021, only ten patents were filed from within South Africa. This disparity underscores the need for an enabling environment that promotes the development of complex cognitive and creative AI systems.

Public Sector Data: The Key to AI-Driven Healthcare

One of the significant hurdles to AI development in Africa is data availability and the costs associated with its acquisition. The National Digital Health Strategy for South Africa 2019 – 2024 identifies the development of a patient electronic health record as a key priority. This record system could provide a wealth of high-quality data to train AI systems, alleviating the significant investment and effort required to curate non-optimised data.

The concept of using public sector data to develop, train, and improve AI-enabled systems is not new. The Declaration of Cooperation on Artificial Intelligence, ratified by 25 European countries in 2018, saw member states agree to ensure better access to public sector data to fuel AI development.

However, access to sensitive health data raises privacy and security concerns. A robust legal framework or governance system is needed to encourage innovation while preserving patient privacy and security. A federated data system, where data do not leave the participating organisation but can be accessed by authorised individuals to train algorithms, could be the solution.

Conclusion

The establishment of a public sector data institution, alongside the proposed patient electronic record, could incentivise the development and deployment of AI for use in healthcare in South Africa. By providing developers with secure and safe access to health data, we can respect the rights to intellectual property and digital authenticity.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.